Photo:
curegt.org
Sep 2, 2026, 06:38
Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
Glanzmann’s Research Foundation shared a post on LinkedIn:
“We’re revisiting a promising 2025 study that offers a hopeful look at the future of Glanzmann Thrombasthenia gene therapy.
Researchers successfully used gene transfer to increase production of the platelet receptor affected by GT in human cells.
Although this was laboratory research, the findings support the next step: testing the approach in stem cells from people with GT.
We’ve broken down the research and what it could mean for patients and families in an easy-to-understand article.”
Other posts about Glanzmann’s Research Foundation on Hemostasis Today.
-
Sep 2, 2026, 15:41Nour Al-Mozain: Rethinking the Role of Cold-Stored Platelets
-
Sep 2, 2026, 15:39Fahad Alshehri: Are All Platelets Created Equal?
-
Sep 2, 2026, 15:09Kim Cook: Bringing Rare Blood Cancers Into the Conversation
-
Sep 2, 2026, 15:08Anupriya Ak: Blood Groups and Transfusion Compatibility
-
Sep 2, 2026, 14:51Amir Hesam Karbakhsh: The Science Behind Platelet-Rich Plasma Preparation
-
Sep 2, 2026, 14:38Brandi Littles Kelly: Raising ITP Awareness Through a Family’s Journey
-
Sep 2, 2026, 14:36Sangita Saha: Hemolysis in Hemodialysis – Causes, Prevention, Patient Safety
-
Sep 2, 2026, 14:31David Smadja: A New School Year, A Stronger Hematology Team
-
Sep 2, 2026, 14:28Khaled Musallam: The 5th MENA Congress for Rare Diseases Is Coming to Abu Dhabi